Genentech Sues Sandoz Over Generic Valcyte

Law360, New York (April 22, 2011, 3:12 PM EDT) -- Roche Holding Ltd. subsidiary Genentech Inc. sued Sandoz Inc. in California on Wednesday, accusing it of infringing a patent covering the anti-viral drug Valcyte.

Genentech and Roche Palo Alto LLC's complaint claims Sandoz — the generics arm of Novartis AG — infringed the patent-in-suit by seeking U.S. Food and Drug Administration approval for a generic version of Valcyte, and seeks to block Sandoz from selling its generic in the U.S. before that patent expires.

Sandoz’s product infringes the Roche crystalline valganciclovir patent, Roche said in a statement,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.